{"id":1361,"date":"2023-02-10T12:08:31","date_gmt":"2023-02-10T12:08:31","guid":{"rendered":"https:\/\/blog.trive.com\/?p=1361"},"modified":"2023-02-10T12:08:31","modified_gmt":"2023-02-10T12:08:31","slug":"astrazeneca-plcs-earnings-surprise-tickles-bullish-investors","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/es\/inversion\/astrazeneca-plcs-ganancias-sorpresa-cosquillas-inversores-alcistas\/","title":{"rendered":"La sorpresa de ganancias de AstraZeneca PLC hace cosquillas a los inversores optimistas\u00a0"},"content":{"rendered":"<p>AstraZeneca PLC (LSE: AZN) entreg\u00f3 un s\u00f3lido 2022 con un crecimiento vertiginoso de 25% en los ingresos totales, a pesar de verse afectado por la disminuci\u00f3n de las ventas de vacunas contra el covid-19 durante la mayor parte de 2022. Los traders alcistas se apresuraron a comprar acciones despu\u00e9s de que las ganancias del cuarto trimestre superaron el consenso por 2.74%, lo que posteriormente hizo subir el precio de las acciones de AstraZeneca 3.7%.&nbsp;<\/p>\n\n\n\n<p>El CEO dio una orientaci\u00f3n positiva para 2023 con expectativas de crecimiento de ingresos de dos d\u00edgitos, excluyendo las vacunas Covid-19, respaldado por un r\u00e9cord de 34 aprobaciones de productos de atenci\u00f3n m\u00e9dica que saldr\u00e1n a la venta en los principales mercados. M\u00e1s all\u00e1 de esto, se prev\u00e9 que el crecimiento de las ventas en los mercados emergentes, particularmente en China, contribuya a la expansi\u00f3n general de los ingresos brutos.&nbsp;&nbsp;<\/p>\n\n\n\n<h2><strong>T\u00e9cnicos<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Las ganancias positivas del tercer trimestre de 2022 impulsaron el precio de las acciones de AstraZeneca al alza, con 9,521 TP3T para formar un m\u00e1ximo hist\u00f3rico y una resistencia de 118,04 libras esterlinas por acci\u00f3n, mientras que el soporte se estableci\u00f3 en 95,10 libras esterlinas por acci\u00f3n.&nbsp;<\/p>\n\n\n\n<p>Un retroceso de la resistencia llev\u00f3 al precio a la proporci\u00f3n \u00e1urea de Fibonacci de 61.8% antes de que se produjera un rechazo. Las ganancias mejores de lo esperado y los fundamentos comerciales saludables atrajeron m\u00e1s alcistas al mercado. Es probable que los inversores alcistas fijen su mirada en el nivel de \u00a3118,04 libras esterlinas por acci\u00f3n como la puerta de salida en caso de que participen en el mercado.&nbsp;<\/p>\n\n\n\n<p>Por otro lado, si el impulso bajista supera al impulso alcista en los niveles actuales, el precio podr\u00eda revertirse y encontrar el camino de regreso hacia el soporte en \u00a395,10 libras esterlinas por acci\u00f3n.&nbsp;&nbsp;<\/p>\n\n\n\n<figure class=\"is-layout-flex wp-block-gallery-1 wp-block-gallery has-nested-images columns-default is-cropped\">\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"1024\" height=\"520\" data-id=\"1362\"  src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-1024x520.png\" alt=\"\" class=\"wp-image-1362\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-1024x520.png 1024w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-300x152.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-768x390.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-1536x780.png 1536w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d-18x9.png 18w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/AZN_2023-02-10_12-54-09_fb58d.png 1834w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/figure>\n\n\n\n<p><\/p>\n\n\n\n<h2><strong>Fundamentales<\/strong>&nbsp;<\/h2>\n\n\n\n<p>Los temores relacionados con la pandemia disminuyeron en 2022, respaldados por ventas m\u00e1s d\u00e9biles de la vacuna Covid-19 (Vaxzevria) en todos los \u00e1mbitos. A pesar de la ca\u00edda en las ventas de vacunas, las ventas de otros productos m\u00e9dicos se mantuvieron elevadas. El crecimiento de ingresos de 25% de AstraZeneca palidece en comparaci\u00f3n con el crecimiento de 34%, sin incluir las ventas de vacunas.&nbsp;&nbsp;<\/p>\n\n\n\n<p>El s\u00f3lido desempe\u00f1o operativo fue respaldado por un crecimiento triple en las ganancias operativas, revelando la salud operativa de AstraZeneca. Los flujos de efectivo de las operaciones aumentaron 46% a\u00f1o con a\u00f1o para cerrar el a\u00f1o en $12B desde $8B. Es probable que los flujos de efectivo de 2023 se vean impulsados por la disminuci\u00f3n de las obligaciones de deuda logradas en 2022, ya que la deuda neta se redujo de 5.75% a $23B.&nbsp;<\/p>\n\n\n\n<p>Las ventas de los mercados desarrollados representan 60% de las ventas totales, seguido por el Resto del mundo, que aporta 40% (de los cuales China constituye 13%). Dado que AstraZeneca est\u00e1 en el negocio de vender bienes de primera necesidad, es poco probable que enfrente severos obst\u00e1culos derivados de la inflaci\u00f3n y su detrimento en el gasto del consumidor, especialmente en econom\u00edas desarrolladas como EE. UU., donde se reconocen 40% de ventas.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<p>Trads descontar los flujos de caja futuros, el valor razonable de AstraZeneca se deriv\u00f3 en \u00a3117,20 libras esterlinas por acci\u00f3n, una prima de 4,8% respecto al precio actual de las acciones.&nbsp;&nbsp;&nbsp;<\/p>\n\n\n\n<h2><strong>Resumen<\/strong>&nbsp;<\/h2>\n\n\n\n<p>La salud financiera y operativa de AstraZeneca para 2022 probablemente se filtrar\u00e1 hasta 2023. Combinado con una orientaci\u00f3n optimista para 2023, el precio de las acciones de AstraZeneca probablemente se magnetizar\u00e1 al alza, dado que no se desarrollan circunstancias comerciales adversas significativas.&nbsp;&nbsp;<\/p>\n\n\n\n<p><em>Fuentes: AstraZeneca, Reuters, TradingView, Koyfin&nbsp;<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022. Bullish traders rushed to buy the stock after Q4 earnings beat consensus by 2.74%, subsequently pushing AstraZeneca&#8217;s share price up 3.7%.&nbsp; The CEO gave positive [&hellip;]<\/p>","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/es\/inversion\/astrazeneca-plcs-ganancias-sorpresa-cosquillas-inversores-alcistas\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/es\/inversion\/astrazeneca-plcs-ganancias-sorpresa-cosquillas-inversores-alcistas\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-10T12:08:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"720\" \/>\n\t<meta property=\"og:image:height\" content=\"405\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\" \/>\n<meta name=\"twitter:description\" content=\"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0\",\"datePublished\":\"2023-02-10T12:08:31+00:00\",\"dateModified\":\"2023-02-10T12:08:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\"},\"wordCount\":463,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\",\"url\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\",\"name\":\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-02-10T12:08:31+00:00\",\"dateModified\":\"2023-02-10T12:08:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/es\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/es\/inversion\/astrazeneca-plcs-ganancias-sorpresa-cosquillas-inversores-alcistas\/","og_locale":"es_ES","og_type":"article","og_title":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors","og_description":"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.","og_url":"https:\/\/blog.trive.com\/es\/inversion\/astrazeneca-plcs-ganancias-sorpresa-cosquillas-inversores-alcistas\/","og_site_name":"Trive Blog","article_published_time":"2023-02-10T12:08:31+00:00","og_image":[{"width":720,"height":405,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors","twitter_description":"AstraZeneca PLC (LSE: AZN) delivered a solid 2022 with a blistering 25% growth in total revenues, despite being weighed down by declining sales of Covid-19 vaccines for most of 2022.","twitter_image":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/Folie1-4.png","twitter_misc":{"Escrito por":"","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/"},"author":{"name":"","@id":""},"headline":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0","datePublished":"2023-02-10T12:08:31+00:00","dateModified":"2023-02-10T12:08:31+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/"},"wordCount":463,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"articleSection":["Investment"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/","url":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/","name":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0 - Trive Blog","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-02-10T12:08:31+00:00","dateModified":"2023-02-10T12:08:31+00:00","breadcrumb":{"@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/investment\/astrazeneca-plcs-earnings-surprise-tickles-bullish-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca PLC\u2019s Earnings Surprise Tickles Bullish Investors\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/es\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/1361"}],"collection":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/comments?post=1361"}],"version-history":[{"count":2,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/1361\/revisions"}],"predecessor-version":[{"id":1365,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/posts\/1361\/revisions\/1365"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/media?parent=1361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/categories?post=1361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/es\/wp-json\/wp\/v2\/tags?post=1361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}